Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.

Autor: Krishna Susarla S; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India. Electronic address: s.saikrishna@indimmune.com., Jahagirdar R; Department of Pediatrics, Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Pune, Maharashtra, India., Ghosh Uttam K; Department of Pediatric Medicine, Institute of Child Health, Kolkata, West Bengal, India., Srikanth Bhatt S; Department of Pediatrics, Gandhi Medical College and Hospital, Secunderabad, Telangana, India., Prashanth S; Department of Pediatrics, Cheluvamba Hospital, Mysore Medical College and Research Institute, Mysore, Karnataka, India., Rajapantula V; Department of Medicine, King George Hospital, Visakhapatnam, Andhra Pradesh, India., Satish M; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India., Rajashakar BC; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India., Sandhya G; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India., Rajendra L; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India., Prasad Sahoo D; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India., Kumar Kanakasapapathy A; Human Biologicals Institute (A Division of Indian Immunologicals Limited), Hyderabad, Telangana, India.

Publikováno v: Vaccine [Vaccine] 2023 Oct 20; Vol. 41 (44), pp. 6558-6564. Date of Electronic Publication: 2023 Aug 31.